Atomizing liquid improver, atomizing liquid, and aerosol generating device

Abstract

The present application discloses an atomizing liquid improver, an atomizing liquid, and an aerosol generating device. The atomizing liquid improver comprises 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one, 3-hydroxycitronellol-3-O-β-D-glucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone, and an antioxidant.

Description

Atomizing liquid modifier, atomizing liquid and aerosol generating device

[0001] This application claims priority to Chinese patent application No. 202311263198.8 filed on September 27, 2023, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present application relates to the field of flavor technology, and in particular to an atomizing liquid modifier, an atomizing liquid, and an aerosol generating device. Background Art

[0003] Atomizer liquid is a liquid used in aerosol-generating devices to produce vapor. It is usually composed of propylene glycol (PG), glycerin (VG), flavorings, nicotine, and other additives. Under normal circumstances, saliva secretion is regulated by nerves and hormones, which helps moisturize, digest, and protect the mouth. Certain chemicals may interfere with saliva secretion in different ways, causing a decrease in saliva secretion. Propylene glycol and glycerin in atomizer flavors are two of them. As commonly used basic ingredients, long-term use of propylene glycol and glycerin can affect saliva secretion disorders and cause long-term dry mouth, which not only affects the user's comfort and user experience, but may also have an adverse effect on oral health. Therefore, solving the problem of dry mouth caused by the use of atomizer liquid can optimize the user experience of atomizer liquid. Technical issues

[0004] The main purpose of this application is to propose an atomized liquid improver, which aims to overcome the long-term oral dryness problem caused by the atomized liquid in the prior art. Technical Solutions

[0005] To achieve the above objectives, the present application proposes an atomized liquid modifier, comprising the following raw material components:

[0006] 6-O-p-Hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one, 3-hydroxy-citronellal 3-O-β-D-glucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone and antioxidants.

[0007] In one embodiment, the antioxidant comprises resveratrol.

[0008] In one embodiment, the atomized liquid modifier comprises the following components in parts by mass:

[0009] 0.10-1 part of 6-O-p-hydroxybenzoyl catalpol;

[0010] 7α-hydroxy-β-sitosterol 0.1~1 part;

[0011] 0.1-0.5 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one;

[0012] 0.1-0.5 parts of 3-hydroxy-citronellal 3-O-β-D-glucopyranoside;

[0013] Resveratrol 0.01~0.05 parts;

[0014] 3',4',5,6,7,8-hexamethoxyflavone and 0.01-0.05 parts of antioxidant.

[0015] The present application also proposes the use of an atomizing liquid modifier in the long-term relief of dry mouth caused by the use of atomized flavors. The atomizing liquid modifier includes raw material components: 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellal 3-O-β-D-pyranoglucoside, 3',4',5,6,7,8-hexamethoxyflavone and antioxidant.

[0016] The present application also proposes an atomized liquid comprising the above-mentioned atomized liquid improver.

[0017] In one embodiment, the atomized liquid further includes glycerol and 1,2-propylene glycol.

[0018] In one embodiment, the mass ratio of glycerin to the atomized liquid modifier is 10:(0.084-0.62).

[0019] The present application also proposes an aerosol generating device, comprising the above-mentioned atomizing liquid. Beneficial effects

[0020] The atomizing liquid modifier provided in this application includes 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone, and an antioxidant. 6-O-p-hydroxybenzoyl catalpol is naturally derived from various plants in the Bignoniaceae and Plantaginaceae families, such as Oroxylum indicum and Plantago asiatica. NF-κB is a key nuclear transcription factor that is associated with various cellular activities such as immune cell activation, T and B lymphocyte development, stress response, and apoptosis. It can regulate many immune and inflammation-related genes and has a certain effect on cell damage repair. Catalpol, an iridoid ether terpenoid glucoside, has been shown to regulate NF-κB. Modifications to functional groups often alter the properties of the compound. Compounds with acyl substitutions at the 6-O position, known as 6-O-acyl catalpols, have stronger NF-κB regulatory effects than catalpol. 7α-Hydroxy-β-sitosterol, a natural product from various plants in the Ranunculaceae family, promotes cell regeneration. 5,7-Dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one has potent oxygen free radical scavenging properties. 3-Hydroxy-citronellal 3-O-β-D-glucopyranoside may interfere with various inflammatory signaling pathways, such as NF-κB and mitochondrial-mediated pathways, suppressing inflammatory responses by inhibiting NF-κB activation. 3',4',5,6,7,8-Hexamethoxyflavone, a natural product from citrus plants such as lime and grapefruit, exhibits antioxidant activity. The combination of the above substances can reduce oral inflammation or cell damage caused by propylene glycol and glycerol, promote the recovery of affected cells or eliminate inflammation, thereby alleviating the reduced saliva secretion caused by propylene glycol and glycerol. The aerosol liquid modifier provided in this application has the technical effect of long-term relief of oral dryness caused by aerosol liquid use. Modes for Carrying Out the Invention

[0021] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or the conditions recommended by the manufacturer. If the reagents or instruments used are not specified by the manufacturer, they are all conventional products that can be purchased commercially. In addition, the meaning of "and / or" appearing in the full text includes three parallel schemes. Taking "A and / or B" as an example, it includes scheme A, or scheme B, or schemes that A and B meet simultaneously. In addition, the technical solutions between the various embodiments can be combined with each other, but must be based on the ability of those of ordinary skill in the art to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist and is not within the scope of protection required by this application. Based on the embodiments in this application, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of this application.

[0022] Atomizer liquid is a liquid used in aerosol-generating devices to produce vapor. It is usually composed of propylene glycol (PG), glycerin (VG), flavorings, nicotine, and other additives. Under normal circumstances, the secretion of saliva is regulated by nerves and hormones, which helps moisturize, digest, and protect the mouth. Certain chemicals may interfere with saliva secretion in different ways, causing a decrease in saliva secretion. Propylene glycol and glycerin in atomizer flavors are two of them. As commonly used basic ingredients, long-term use of propylene glycol and glycerin can affect saliva secretion disorders and cause long-term dry mouth, which not only affects the user's comfort and user experience, but may also have an adverse effect on oral health. Therefore, solving the problem of dry mouth caused by the use of atomizer liquid can optimize the user experience of atomizer liquid.

[0023] In view of this, the present application proposes an atomizing liquid modifier, which aims to overcome the problem of dry mouth caused by the use of atomizing liquid in the prior art. The raw material components of the atomizing liquid modifier include 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellic acid 3-O-β-D-pyranoside, 3',4',5,6,7,8-hexamethoxyflavone and antioxidant.

[0024] The atomizing liquid modifier provided in this application includes 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone and antioxidant. 6-O-p-hydroxybenzoyl catalpol is naturally derived from various plants of the Bignoniaceae and Plantaginaceae families, such as Oroxylum indicum and Plantain. NF-κB is a key nuclear transcription factor that is associated with various cellular activities such as immune cell activation, T and B lymphocyte development, stress response, and apoptosis. It can regulate many immune and inflammation-related genes and has a certain effect on cell damage repair. Catalpol, a terpenoid glucoside, plays a role in NF-κB regulation. Modifications to functional groups often alter the properties of the compound. Compounds with acyl substitutions at the 6-O position, known as 6-O-acyl catalpols, exhibit stronger NF-κB regulation. 7α-Hydroxy-β-sitosterol, a natural product from various plants in the Ranunculaceae family, promotes cell regeneration. 5,7-Dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one is a potent oxygen free radical scavenger. 3-Hydroxy-citronellal 3-O-β-D-glucopyranoside may interfere with various inflammatory signaling pathways, such as the NF-κB pathway and mitochondrial-mediated pathways, suppressing inflammatory responses by inhibiting NF-κB activation. 3',4',5,6,7,8-Hexamethoxyflavone, a natural product from citrus plants such as lime and grapefruit, exhibits antioxidant activity. The combination of the above substances can reduce oral inflammation or cell damage caused by propylene glycol and glycerol, promote the recovery of affected cells or eliminate inflammation, thereby alleviating the reduced saliva secretion caused by propylene glycol and glycerol. The aerosol liquid modifier provided in this application has the technical effect of long-term relief of oral dryness caused by aerosol liquid use.

[0025] The antioxidant includes resveratrol. Resveratrol is naturally derived from grape skin and is an important physiologically active polyphenol. It is the main active ingredient in many plants. The antioxidant can also be other antioxidants such as quercetin. However, when combined with other raw materials, these antioxidants are not as effective as resveratrol in alleviating the problem of dry mouth caused by the use of aerosol liquid. Therefore, in one embodiment of the present application, the use of resveratrol can further provide long-term relief for the problem of dry mouth caused by the use of aerosol liquid.

[0026] Furthermore, the aerosol improver comprises the following components, measured by mass: 0.10-1 part of 6-O-p-hydroxybenzoyl catalpol; 0.1-1 part of 7α-hydroxy-β-sitosterol; 0.1-0.5 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one; 0.1-0.5 part of 3-hydroxy-citronellal 3-O-β-D-glucopyranoside; 0.01-0.05 part of resveratrol; 0.01-0.05 part of 3',4',5,6,7,8-hexamethoxyflavone; and 0.01-0.05 part of an antioxidant. Using the above mass fractions can better and long-term alleviate the problem of dry mouth caused by the use of aerosol.

[0027] The present application also proposes the use of an atomizing liquid modifier for long-term relief of oral dryness caused by the use of atomizing liquid. The atomizing liquid modifier comprises the following raw material components: 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone, and an antioxidant. The application also proposes the use of an atomizing liquid modifier for long-term relief of oral dryness caused by the use of atomizing liquid, which can achieve long-term relief of the problem of oral dryness caused by the use of atomizing liquid.

[0028] This application also proposes an atomized liquid, including the atomized liquid modifier. The atomized liquid has all the technical solutions of the atomized liquid modifier, and thus has all the beneficial effects of the atomized liquid modifier, which will not be described in detail in this application.

[0029] Furthermore, the aerosol liquid further comprises glycerol and 1,2-propylene glycol, with the mass ratio of glycerol to the aerosol liquid modifier being 10:(0.084-0.62). At this mass ratio, the aerosol liquid modifier has a better long-term effect in alleviating oral dryness caused by the use of the aerosol liquid.

[0030] The preparation method of the atomized liquid proposed in the present application is: adding the above-mentioned atomized liquid modifier to glycerol, and then adding 1,2-propylene glycol to obtain a mixed liquid, and stirring the mixed liquid for 5 minutes to obtain the atomized liquid.

[0031] This application also proposes an aerosol generating device, including the atomized liquid. The aerosol generating device has all the technical solutions of the atomized liquid modifier, and thus has all the beneficial effects of the atomized liquid modifier, which will not be described in detail in this application.

[0032] The technical solution of the present application is further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only used to explain the present application and are not used to limit the present application.

[0033] Example 1

[0034] The raw material components of the atomizing liquid modifier are: 6-O-p-hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellal acid 3-O-β-D-pyranoglucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone, and resveratrol.

[0035] Example 2

[0036] The raw material components and corresponding mass fractions of the atomizing liquid modifier are: 0.05 parts of 6-O-p-hydroxybenzoyl catalpol, 0.05 parts of 7α-hydroxy-β-sitosterol, 0.01 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.01 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.001 parts of 3',4',5,6,7,8-hexamethoxyflavone, and 0.001 parts of resveratrol.

[0037] Example 3

[0038] The raw material components and corresponding mass fractions of the atomizing liquid modifier are: 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.05 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 part of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.005 part of 3',4',5,6,7,8-hexamethoxyflavone, and 0.005 part of resveratrol.

[0039] Example 4

[0040] The raw material components and corresponding mass fractions of the atomizing liquid modifier are: 0.2 parts of 6-O-p-hydroxybenzoyl catalpol, 0.2 parts of 7α-hydroxy-β-sitosterol, 0.1 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.1 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.01 parts of 3',4',5,6,7,8-hexamethoxyflavone, and 0.01 parts of resveratrol.

[0041] Example 5

[0042] The raw material components and corresponding mass fractions of the atomizing liquid modifier are: 1 part of 6-O-p-hydroxybenzoyl catalpol, 1 part of 7α-hydroxy-β-sitosterol, 0.5 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.5 part of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.05 part of 3',4',5,6,7,8-hexamethoxyflavone, and 0.05 part of resveratrol.

[0043] Example 6

[0044] The raw material components and corresponding mass fractions of the atomizing liquid modifier are: 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.2 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.2 part of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.02 part of 3',4',5,6,7,8-hexamethoxyflavone, and 0.02 part of resveratrol.

[0045] Example 7

[0046] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.05 parts of 6-O-p-hydroxybenzoyl catalpol, 0.05 parts of 7α-hydroxy-β-sitosterol, 0.01 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.01 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.001 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.001 parts of resveratrol and 49.878 parts of 1,2-propylene glycol.

[0047] Example 8

[0048] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.05 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 part of 3-hydroxy-citronellal acid 3-O-β-D-pyranoglucopyranoside, 0.005 part of 3',4',5,6,7,8-hexamethoxyflavone, 0.005 part of resveratrol and 49.69 parts of 1,2-propylene glycol.

[0049] Example 9

[0050] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.2 parts of 6-O-p-hydroxybenzoyl catalpol, 0.2 parts of 7α-hydroxy-β-sitosterol, 0.1 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.1 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.01 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.01 parts of resveratrol and 49.38 parts of 1,2-propylene glycol.

[0051] Example 10

[0052] The composition of the nebulizer liquid includes: 50 parts of glycerol, 1 part of 6-O-p-hydroxybenzoyl catalpol, 1 part of 7α-hydroxy-β-sitosterol, 0.5 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.5 part of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.05 part of 3',4',5,6,7,8-hexamethoxyflavone, 0.05 part of resveratrol and 46.9 parts of 1,2-propylene glycol.

[0053] Example 11

[0054] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.2 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.2 part of 3-hydroxy-citronellal acid 3-O-β-D-pyranoglucopyranoside, 0.02 part of 3',4',5,6,7,8-hexamethoxyflavone, 0.02 part of resveratrol and 49.36 parts of 1,2-propylene glycol.

[0055] Comparative Example 1

[0056] The composition of the atomizing liquid includes: 50 parts of glycerol and 50 parts of 1,2-propylene glycol.

[0057] Comparative Example 2

[0058] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 parts of 7α-hydroxy-β-sitosterol, 0.05 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 parts of 3-hydroxy-citronellal acid 3-O-β-D-pyranoglucopyranoside, 0.005 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.005 parts of resveratrol and 49.79 parts of 1,2-propylene glycol.

[0059] Comparative Example 3

[0060] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 parts of 6-O-p-hydroxybenzoyl catalpol, 0.05 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.005 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.005 parts of resveratrol and 49.79 parts of 1,2-propylene glycol.

[0061] Comparative Example 4

[0062] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 parts of 6-O-p-hydroxybenzoyl catalpol, 0.1 parts of 7α-hydroxy-β-sitosterol, 0.05 parts of 3-hydroxy-citronellal 3-O-β-D-pyranoglucopyranoside, 0.005 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.005 parts of resveratrol and 49.74 parts of 1,2-propylene glycol.

[0063] Comparative Example 5

[0064] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 parts of 6-O-p-hydroxybenzoyl catalpol, 0.1 parts of 7α-hydroxy-β-sitosterol, 0.05 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.005 parts of 3',4',5,6,7,8-hexamethoxyflavone, 0.005 parts of resveratrol and 49.74 parts of 1,2-propylene glycol.

[0065] Comparative Example 6

[0066] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.05 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 part of 3-hydroxy-citronellal 3-O-β-D-pyranoglucoside, 0.005 part of resveratrol and 49.695 parts of 1,2-propylene glycol.

[0067] Comparative Example 7

[0068] The composition of the nebulizer liquid includes: 50 parts of glycerol, 0.1 part of 6-O-p-hydroxybenzoyl catalpol, 0.1 part of 7α-hydroxy-β-sitosterol, 0.05 part of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 0.05 part of 3-hydroxy-citronellic acid 3-O-β-D-pyranoglucoside, 0.005 part of 3',4',5,6,7,8-hexamethoxyflavone and 49.695 parts of 1,2-propylene glycol.

[0069] Test methods and results

[0070] 1. Preparation before testing:

[0071] Healthy male SD rats aged 7-8 weeks and weighing 180-200 g were randomly divided into 13 groups, with 6 rats in each group.

[0072] The aerosolized liquids obtained in Examples 7-11 and Comparative Examples 1-7 were added to the aerosol generating device, and the aerosol was released by heating after power was applied. 35 ml of aerosol was released each time, and 0.3 ml of aerosol was diverted to the oral aerosol delivery system and delivered to the oral cavity of rats in groups 1-12, respectively. The treatment was performed every 30 seconds, 200 times per day, for 7 days.

[0073] The rats in group 13 were not treated with the aerosol solution and served as the blank control group.

[0074] 2. Testing indicators and methods:

[0075] Indicators: The test indicators are the saliva secretion volume of rats in each group 1 day before treatment and 3 days, 7 days, 15 days, and 30 days after treatment. The indicator on the first day is the control group within the group.

[0076] Methods: Before measurement, sterile absorbent cotton balls were weighed dry and weighed to 26 ± 0.17 mg. Saliva secretion was measured by placing the weighed cotton balls in the rat's cheek. Each cotton ball was replaced every 30 minutes for 60 minutes. The maximum saliva secretion was calculated by the difference in weight between the dry cotton balls before and after weighing.

[0077] Saliva secretion (mg) = wet weight of dry cotton ball - dry weight of dry cotton ball

[0078] The test results are shown in Table 1:

[0079] Table 1 Saliva secretion of rats in Examples 7 to 11, Comparative Examples 1 to 7 and the control group for 3-30 days

[0080] Group Saliva secretion volume before day 1 (mg) Saliva secretion volume on day 3 (mg) Saliva secretion volume on day 7 (mg) Saliva secretion volume on day 15 (mg) Saliva secretion volume on day 30 (mg) Example 7 46.832±0.635 40.790±2.035 41.059±0.779 43.006±1.302 45.65±0.705 Example 8 46.755±0.833 48.713±1.732 46.531±2.232 46.706±2.170 46.355±1.325 Example 9 46.527±0.751 51.235±1.325 48.77 2±1.05947.655±2.03346.324±1.652Example 1046.468±0.56252.941±0.52449.168±1.26947.882±1.92446.559±1.376Example 1146.665±0.45350.238±1.05648.367±0.87646.934±1.57546.468±1.253Comparative Example 146.650±0.77033.677±1.33733.860±0.67334.179±0.89235.166±1.24 6Comparative Example 2 46.395±0.739 36.862±1.468 37.254±0.964 38.345±2.376 40.798±1.364 Comparative Example 3 46.640±0.784 35.397±1.285 36.834±1.642 37.788±1.228 39.354±0.879 Comparative Example 4 46.775±0.529 36.840±0.862 36.982±0.952 38.247±0.736 38.657±1.523 Comparative Example 5 46.628±1.063 37.695±0.936 37. 924±1.36438.445±1.86539.248±0.617Comparative Example646.673±0.51736.670±1.25337.456±2.64239.673±0.92740.213±2.165Comparative Example746.458±0.84238.177±1.16838.768±0.95440.354±1.16042.786±1.395Control Group46.779±0.63446.880±0.87346.578±0.99346.856±1.03246.602±1.005

[0081] Table 2 Percentage increase in saliva secretion of rats in Examples 7 to 11, Comparative Examples 1 to 7, and the control group 3-30 days after treatment relative to the saliva secretion before treatment

[0082] Group Percentage increase in saliva secretion on day 3 Percentage increase in saliva secretion on day 7 Percentage increase in saliva secretion on day 15 Percentage increase in saliva secretion on day 30 Example 7 -12.90% -12.33% -8.17% -2.52% Example 8 4.19% -0.48% -0.10% -0.86% Example 9 10.12% 4.83% 2.42% -0.44% Example 10 13.93% 5.81% 3.04% 0.20% Example 1 17.66% 3.65% 0.58% -0.42% Comparative Example 1 -27.81% -27.42% -26.73% -24 .62%Comparative Example 2-20.55%-19.70%-17.35%-12.06%Comparative Example 3-24.11%-21.02%-18.98%-15.62%Comparative Example 4-21.24%-20.94%-18.23%-17.36%Comparative Example 5-19.16%-18.67%-17.55%-15.83%Comparative Example 6-21.43%-19.75%-15.00%-13.84%Comparative Example 7-17.82%-16.55%-13.14%-7.90%Control Group 0.22%-0.43%0.16%-0.38%

[0083] There was no significant difference in the saliva secretion volume of rats in the control group that were not treated with the nebulized liquid one day before and on the third, seventh, fifteenth and 30th days, indicating that under the same living conditions, the saliva secretion volume of rats without any treatment remained stable.

[0084] The saliva secretion of rats treated with the aerosolized liquid prepared in Example 11 was significantly different between the day before treatment and the day after treatment, indicating that the aerosol in the control group had an effect on the saliva secretion of the rats, that is, the propylene glycol and glycerol caused salivary secretion disturbances in the rats, and that this effect lasted for a period of time.

[0085] The difference in saliva secretion between the rats treated with the aerosolized liquid prepared in Examples 7 to 10 and the rats before treatment was within 5 mg. The saliva secretion of the rats treated with the aerosolized liquid prepared in Example 7 was slightly reduced within 15 days, but it had a greater effect on alleviating the decrease in saliva secretion than that of the rats treated with the aerosolized liquid prepared in Comparative Example 1.

[0086] Compared with the saliva secretion of rats treated with the atomized liquid prepared in Examples 8 to 10 one day before treatment, the saliva secretion of rats was vigorous within 7 days, and normal saliva secretion function was restored on the 15th day, and continued to the 30th day. Compared with the rats treated with the atomized liquid prepared in Comparative Example 1, the atomized liquid had a greater and more sustained effect in alleviating the decrease in saliva secretion.

[0087] In summary, the nebulized liquid modifier provided in the present application can alleviate the salivary secretion disorder caused by propylene glycol and glycerin in the nebulized liquid and can provide long-term relief, thereby expanding the use scenarios of the nebulized liquid.

[0088] The above are merely optional embodiments of the present application and are not intended to limit the scope of the present invention. Those skilled in the art will readily appreciate that various modifications and variations are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present application shall be included within the scope of the present invention.

Claims

1. An atomized liquid improver, wherein: The atomized liquid improver comprises the following raw material components: 6-O-p-Hydroxybenzoyl catalpol, 7α-hydroxy-β-sitosterol, 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl) chroman-4-one, 3-hydroxy-citronellic acid 3-O-β-D-pyranoglucopyranoside, 3',4',5,6,7,8-hexamethoxyflavone and antioxidants.

2. The atomized liquid improver according to claim 1, wherein The antioxidant includes resveratrol.

3. The atomized liquid improver according to claim 2, wherein: The atomized liquid improver comprises the following components in parts by mass: 6-O-p-hydroxybenzoyl catalpol 0.10-1 part; 7α-hydroxy-β-sitosterol 0.1~1 part; 0.1-0.5 parts of 5,7-dihydroxy-6,8-dimethyl-3-(4'-hydroxy-3',5'-dimethoxybenzyl)chroman-4-one; 3-Hydroxy-citronellal acid 3-O-β-D-pyranoglucoside 0.1-0.5 parts; 0.01-0.05 parts of resveratrol; and 3',4',5,6,7,8-hexamethoxyflavone and antioxidant 0.01-0.05 parts.

4. Use of the atomized liquid modifier according to any one of claims 1 to 3 in long-term relief of oral dryness caused by atomized flavors.

5. An atomized liquid, wherein: The atomized liquid comprises the atomized liquid improver as described in any one of claims 1 to 3.

6. The atomized liquid according to claim 5, wherein: The atomizing liquid also includes glycerol and 1,2-propylene glycol.

7. The atomized liquid according to claim 6, wherein: The mass ratio of glycerol to atomizing liquid improver is 10:(0.084~0.62).

8. An aerosol generating device, wherein: The aerosol generating device comprises an aerosolized liquid as claimed in any one of claims 5 to 7.

Images